Digital assay development

SpinChip Diagnostics is developing a game changing platform for medical analysis. The SpinChip platform enables earlier diagnosis of serious health conditions by moving diagnostics from centralized laboratories to the point of need. Early knowledge is key to ensure correct patient treatment and improving quality of life. SpinChip Diagnostics has a mission with the following goals: SpinChip will be a leading contributor to better and more efficient diagnoses. Early initiation of correct treatment will save lives, improve patient well-being and at same time minimize use of incorrect medications. Therefore, correct and quick diagnoses will save costs for both public and private health-organizations Key to the SpinChip platform is its innovative and effective microfluidic processing system. This technology enables the development of a range of diagnostic tests. SpinChip has already designed, developed, and tested the generic platform with biochemical assays for myocardial infarction (cTnI), heart failure (BNP and NT-proBNP) and inflammatory diseases (CRP). The Digital assay development project is of essence to realize the value creation potential of the SpinChip platform by simplifying the process of developing new assays. Through the project, SpinChip Diagnostics has gained models and methods for simulation of complex microfluidic processes taking place within the assay cartridge. The increased insight result in higher quality assays, while reducing development time by fewer iterations with machined prototypes. The project has further contributed to significant datasets that form the foundation for advanced computer vision algorithms. Generic algorithms for real-time monitoring of microfluidics, chemistry and processing have been developed and implemented in the platform as part of the project, and systems are in place to continue to expand the databases of image data and knowledge from both internal and external SpinChip Analyzers. SpinChip Diagnostics have established a production in Oslo and are conducting verification and validation as a part of commercialization of the platform. Project results are essential to meet regulatory requirements for the initial tests launched, as well as drive faster development of new valuable, high-quality tests to the platform in the future.

SpinChip Diagnostics har en misjon med følgende målsetning: SpinChip vil være en ledende bidragsyter til bedre og mer effektive diagnoser. Tidlig initiering av riktig behandling vil redde liv, forbedre pasientens velvære og samtidig minimere bruken av feil medisiner. Derfor vil riktige og raske diagnoser spare kostnader for både offentlige og private helseorganisasjoner. Prosjektet har utrustet SpinChip med kraftive verktøy for å nå dette målet, og som vil fortsette å bidra etterhvert som plattformen utvides med flere verdiskapende analyser.

SpinChip Diagnostics is developing a game changing platform for medical analysis (the SpinChip platform). The SpinChip platform enables earlier diagnosis of serious health conditions by moving diagnostics from centralized laboratories to the point of need. Early knowledge is key to ensure correct patient treatment and improving quality of life. Key to the SpinChip platform is its innovative and effective microfluidic processing system. This technology enables the development of a range of diagnostic tests. SpinChip has already designed, developed, and tested the generic platform with two biochemical assays; high-sensitivity cardiac Troponin I (cTnI) for myocardial infarction, and C-reactive protein (CRP) for inflammatory diseases. The Digital assay development project is of essence to realize the value creation potential of the SpinChip platform by simplifying the process of developing new assays. The project will develop microfluidic models and methods to study the processes taking place within the assay cartridge, where strong centrifugal forces, complex structures, multiphase flows with solids contribute to major R&D challenges. Advanced computer vision- and machine learning algorithms will also be developed for process control, taking advantage of the large amount of image data acquired from each individual test. SINTEF Digital is R&D partner in the project with experience within the relevant fields.